JP2013522313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522313A5 JP2013522313A5 JP2013500181A JP2013500181A JP2013522313A5 JP 2013522313 A5 JP2013522313 A5 JP 2013522313A5 JP 2013500181 A JP2013500181 A JP 2013500181A JP 2013500181 A JP2013500181 A JP 2013500181A JP 2013522313 A5 JP2013522313 A5 JP 2013522313A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- antigen
- ngf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 75
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 17
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 17
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 14
- 229920000053 polysorbate 80 Polymers 0.000 claims 14
- 229940068968 polysorbate 80 Drugs 0.000 claims 14
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 11
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 11
- 229920005862 polyol Polymers 0.000 claims 8
- 150000003077 polyols Chemical class 0.000 claims 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 7
- 229930195725 Mannitol Natural products 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 7
- 150000001720 carbohydrates Chemical class 0.000 claims 7
- 239000000594 mannitol Substances 0.000 claims 7
- 235000010355 mannitol Nutrition 0.000 claims 7
- 229930006000 Sucrose Natural products 0.000 claims 6
- 239000005720 sucrose Substances 0.000 claims 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 229940035676 analgesics Drugs 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000046917 human NGF Human genes 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 claims 1
- 101000996663 Homo sapiens Neurotrophin-4 Proteins 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108090000742 Neurotrophin 3 Proteins 0.000 claims 1
- 102100029268 Neurotrophin-3 Human genes 0.000 claims 1
- 102000003683 Neurotrophin-4 Human genes 0.000 claims 1
- 108090000099 Neurotrophin-4 Proteins 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 101100404655 Rattus norvegicus Ngf gene Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003837 chick embryo Anatomy 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 102000051542 human BDNF Human genes 0.000 claims 1
- 102000057714 human NTF3 Human genes 0.000 claims 1
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000014511 neuron projection development Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229940032018 neurotrophin 3 Drugs 0.000 claims 1
- 229940097998 neurotrophin 4 Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 210000003594 spinal ganglia Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31498410P | 2010-03-17 | 2010-03-17 | |
| US61/314,984 | 2010-03-17 | ||
| PCT/US2011/028659 WO2011116090A1 (en) | 2010-03-17 | 2011-03-16 | Anti-nerve growth factor (ngf) antibody compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522313A JP2013522313A (ja) | 2013-06-13 |
| JP2013522313A5 true JP2013522313A5 (https=) | 2014-05-01 |
Family
ID=44114427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500181A Pending JP2013522313A (ja) | 2010-03-17 | 2011-03-16 | 抗神経成長因子（ｎｇｆ）抗体組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20110256135A1 (https=) |
| EP (1) | EP2547365A1 (https=) |
| JP (1) | JP2013522313A (https=) |
| KR (1) | KR20130031247A (https=) |
| CN (1) | CN102892430A (https=) |
| AR (1) | AR080685A1 (https=) |
| AU (1) | AU2011227335B2 (https=) |
| BR (1) | BR112012023895A2 (https=) |
| CA (1) | CA2790699A1 (https=) |
| CL (1) | CL2012002536A1 (https=) |
| CO (1) | CO6640289A2 (https=) |
| CR (1) | CR20120490A (https=) |
| DO (1) | DOP2012000246A (https=) |
| EC (1) | ECSP12012211A (https=) |
| GT (1) | GT201200258A (https=) |
| MX (1) | MX2012010728A (https=) |
| NZ (1) | NZ602054A (https=) |
| PE (1) | PE20130203A1 (https=) |
| PH (1) | PH12012501761A1 (https=) |
| RU (1) | RU2012144017A (https=) |
| SG (2) | SG183983A1 (https=) |
| TW (1) | TW201201835A (https=) |
| UY (1) | UY33280A (https=) |
| WO (1) | WO2011116090A1 (https=) |
| ZA (1) | ZA201206761B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| SG175436A1 (en) | 2009-05-04 | 2011-12-29 | Abbott Res Bv | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
| JOP20190250A1 (ar) * | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| CA2810731A1 (en) | 2010-09-17 | 2012-03-22 | Baxter International Inc. | Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph |
| JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ｎｇｆ組成物およびその使用 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| KR20220041957A (ko) * | 2013-03-15 | 2022-04-01 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
| TWI679019B (zh) * | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| JP7156777B2 (ja) * | 2013-11-29 | 2022-10-19 | ジェネンテック， インコーポレイテッド | 抗体選択装置及び方法 |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| JPWO2017164349A1 (ja) | 2016-03-25 | 2019-02-07 | アステラス製薬株式会社 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ’フラグメント含有医薬組成物 |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN114751982B (zh) * | 2017-12-15 | 2023-06-23 | 安源医药科技（上海）有限公司 | 抗人ngf抗体及其制备方法和用途 |
| KR20210043624A (ko) * | 2018-08-10 | 2021-04-21 | 리제너론 파아마슈티컬스, 인크. | 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물 |
| IT201800009384A1 (it) | 2018-10-11 | 2020-04-11 | Cosmo Srl | Peptide for cosmetic application |
| AU2019250128A1 (en) | 2018-10-15 | 2020-04-30 | Avent Inc. | Compositions, systems, kits, and methods for neural ablation |
| KR102885113B1 (ko) | 2018-10-18 | 2025-11-13 | 머크 샤프 앤드 돔 엘엘씨 | 항-rsv 항체의 제제 및 그의 사용 방법 |
| CN120842406A (zh) | 2018-10-31 | 2025-10-28 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| KR102735988B1 (ko) | 2019-02-18 | 2024-12-03 | 일라이 릴리 앤드 캄파니 | 치료 항체 제제 |
| BR112021002290A2 (pt) * | 2019-03-26 | 2021-05-04 | Remegen Co., Ltd. | formulações farmacêuticas líquida aquosa e liofilizada de um conjugado anticorpo-fármaco, uso e método para preparar as ditas formulações |
| WO2020233534A1 (zh) * | 2019-05-17 | 2020-11-26 | 百奥泰生物制药股份有限公司 | 抗体-药物偶联物制剂、制备方法及应用 |
| KR102265434B1 (ko) * | 2019-08-20 | 2021-06-15 | 주식회사 케어젠 | 피부 미백 활성을 갖는 펩타이드 및 이의 용도 |
| ES3063234T3 (en) * | 2019-12-20 | 2026-04-15 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN117186219B (zh) * | 2020-04-17 | 2024-07-12 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
| US11492394B1 (en) * | 2021-10-29 | 2022-11-08 | Nascent Biotech, Inc. | Kits and containers for treating vimentin expressing tumors |
| WO2025077862A1 (zh) * | 2023-10-12 | 2025-04-17 | 舒泰神（北京）生物制药股份有限公司 | 一种NGF-Fc融合蛋白制剂及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1992019244A2 (en) | 1991-05-01 | 1992-11-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US6548062B2 (en) | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| DK1401498T3 (da) | 2001-05-30 | 2011-11-21 | Genentech Inc | Anti-NGF-antistoffer til behandlingen af forskellige sygdomme |
| CA2454587C (en) * | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| CN102408483B (zh) | 2003-07-15 | 2016-06-08 | 安姆根有限公司 | 作为选择性ngf途径抑制剂的人抗ngf中和抗体 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| WO2006077441A1 (en) | 2005-01-24 | 2006-07-27 | Cambridge Antibody Technology Limited | Specific binding members for ngf |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| KR101396797B1 (ko) | 2006-06-30 | 2014-05-26 | 애브비 바이오테크놀로지 리미티드 | 자동 주사 장치 |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| CN102159204B (zh) * | 2008-09-19 | 2015-04-01 | 辉瑞公司 | 稳定的液体抗体制剂 |
| SG175436A1 (en) | 2009-05-04 | 2011-12-29 | Abbott Res Bv | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
-
2011
- 2011-03-16 PE PE2012001560A patent/PE20130203A1/es not_active Application Discontinuation
- 2011-03-16 SG SG2012066866A patent/SG183983A1/en unknown
- 2011-03-16 WO PCT/US2011/028659 patent/WO2011116090A1/en not_active Ceased
- 2011-03-16 BR BR112012023895A patent/BR112012023895A2/pt not_active IP Right Cessation
- 2011-03-16 UY UY0001033280A patent/UY33280A/es not_active Application Discontinuation
- 2011-03-16 RU RU2012144017/10A patent/RU2012144017A/ru not_active Application Discontinuation
- 2011-03-16 AU AU2011227335A patent/AU2011227335B2/en not_active Ceased
- 2011-03-16 EP EP11715322A patent/EP2547365A1/en not_active Withdrawn
- 2011-03-16 SG SG10201504808XA patent/SG10201504808XA/en unknown
- 2011-03-16 TW TW100109071A patent/TW201201835A/zh unknown
- 2011-03-16 NZ NZ602054A patent/NZ602054A/en not_active IP Right Cessation
- 2011-03-16 CA CA2790699A patent/CA2790699A1/en not_active Abandoned
- 2011-03-16 JP JP2013500181A patent/JP2013522313A/ja active Pending
- 2011-03-16 CN CN201180023857XA patent/CN102892430A/zh active Pending
- 2011-03-16 MX MX2012010728A patent/MX2012010728A/es not_active Application Discontinuation
- 2011-03-16 KR KR1020127026996A patent/KR20130031247A/ko not_active Withdrawn
- 2011-03-16 AR ARP110100852A patent/AR080685A1/es unknown
- 2011-03-16 US US13/049,473 patent/US20110256135A1/en not_active Abandoned
- 2011-03-16 PH PH1/2012/501761A patent/PH12012501761A1/en unknown
-
2012
- 2012-09-10 ZA ZA2012/06761A patent/ZA201206761B/en unknown
- 2012-09-13 CL CL2012002536A patent/CL2012002536A1/es unknown
- 2012-09-13 DO DO2012000246A patent/DOP2012000246A/es unknown
- 2012-09-13 GT GT201200258A patent/GT201200258A/es unknown
- 2012-09-27 CR CR20120490A patent/CR20120490A/es unknown
- 2012-10-02 EC EC2012012211A patent/ECSP12012211A/es unknown
- 2012-10-05 CO CO12175503A patent/CO6640289A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522313A5 (https=) | ||
| RU2011149263A (ru) | Антитела против фактора роста нервов (фрн), обладающие повышенной стабильностью in vivo | |
| TWI705827B (zh) | 治療眼部疾病之方法 | |
| US12377144B2 (en) | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen | |
| ES2742868T3 (es) | Formulaciones de anticuerpos anti-receptor de prolactina | |
| ES2760002T3 (es) | Métodos de tratamiento de la psoriasis de uñas y cuero cabelludo | |
| JP2008528638A5 (https=) | ||
| US20230382989A1 (en) | Treatment for neoplastic diseases | |
| CN108404127B (zh) | 恶病质治疗 | |
| CN1466464A (zh) | 癌症治疗药 | |
| JP2010531140A5 (https=) | ||
| RU2012144017A (ru) | Композиции антител против фактора роста нервов (ngf) | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN118355025A (zh) | 肥大细胞相关障碍的治疗 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP7660507B2 (ja) | レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法 | |
| ES3057414T3 (en) | Interleukin 5 binding protein dosage regimen | |
| EP3210616A1 (en) | Use of macrophage inflammatory protein-1 (mip-1 ) inhibitor to protect pancreas and prevent blood sugar from rising | |
| ES2444569T3 (es) | Quimera IL-6R/IL-6 para terapia de neuropatía periférica inducida por quimioterapia | |
| WO2025201522A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤 | |
| WO2025252039A1 (zh) | 抗her2抗体药物偶联物治疗非小细胞肺癌的用途 | |
| WO2025162211A1 (zh) | 抗her2抗体药物偶联物治疗胃癌的用途 | |
| WO2022148279A1 (zh) | 药物产品及其用途 | |
| RU2020134794A (ru) | Способы лечения хронической спонтанной крапивницы с применением лигелизумаба |